Shares of Biogen Inc. BIIB inched 0.44% higher to $204.20 Wednesday, on what proved to be an all-around grim trading session ...

Shares of Biogen Inc. BIIB slid 0.76% to $203.30 Tuesday, on what proved to be an all-around great trading session for the ...

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug ...

Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency approved Eisai Co., Ltd (OTC:ESAIY) (OTC:ESALF) and Biogen Inc’s (NASDAQ:BIIB) Leqembi (lecanemab). Lecanemab is ...

Zacks Biogen Q2 Earnings & Sales Beat, 2024 Guidance Raised Biogen (NASDAQ: BIIB) reported second-quarter 2024 adjusted earnings per share of $5.28, beating the Zacks Consensus Estimate of $4.00.

Viehbacher said Biogen is not “desperate” for a deal, either. With HI-Bio coming into the fold, its products are expected to land on the market in the 2027 to 2030 timeframe.Later, Viehbacher ...

(Reuters) -Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S. adoption of its Alzheimer's drug ...

Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s expected of untreated ...

Marc Goodman, an analyst from Leerink Partners, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target is $310.00. Marc Goodman has given his Buy rating due to ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target remains the same with $285.00. Ami Fadia’s rating is based on the ...